Introduction : The mechanisms underlying the development of pulmonary hypertension (PH) and its severity in chronic lung diseases (CLD) are unknown. The study aimed to assess the protein expression profile in plasma in patients with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD), according to the presence and severity of PH, and explore similarities with idiopathic pulmonary arterial hypertension (iPAH). Methods: We analysed 115 patients with CLD: 40 non-PH (19 COPD, 21 ILD), 41 with moderate PH (22 COPD, 19 ILD) and 34 with severe PH (21 COPD, 13 ILD); and 38 patients with iPAH. Plasma samples were analysed by liquid chromatography-mass spectrometry. Student t-tests were used to calculate each comparison and false discovery rates computed. Proteins with a fold change >|1.5|, p-value80% cases of the cohort were selected. Results: CLD-PH had up-regulated proteins from the immunoglobulin superfamily (IgSF) compared with non-PH. Compared with CLD patients with moderate PH, those with severe PH had 6 IgSF proteins and lysozyme up-regulated; and keratin-1 down-regulated. Compared with iPAH, patients with CLD- severe PH had up-regulated 6 IgSF proteins, orosomucoid-1 and tenascin-C; and down-regulated IGF-binding protein-3 and tetranectin. Conclusions: Patients with CLD and PH show a distinct proteomic profile, particularly in IgSF expression, which is further amplified in severe PH. Patients with CLD- severe PH also differ from iPAH, specially in IgSF. Further studies are warranted to assess the functionality of IgSF proteins and their clinical implications in CLD-PH. Supported by PI18/00383 (ISCiii) and FCHP grants. OTC by MS contract, CP17/00114 (ISCiii)
Pulmonary endarterectomy (PEA) specimens provide a unique source of endothelial cells (ECs) to model chronic thromboembolic pulmonary hypertension (CTEPH) in vitro. This study investigates the impact of chronic hypoxia on PEA-derived ECs, focusing on mechanisms of endothelial dysfunction and vascular remodeling. ECs from PEA specimens (EC-CTEPH) and controls were exposed to normoxia, hypoxia, and reoxygenation. Cell morphology, proliferation, migration, and expression of angiogenic and hypoxia-responsive genes were assessed. Pharmacological HIF stabilization with dimethyloxalylglycine (DMOG) was compared with hypoxia. Oxidative stress responses were evaluated using hydrogen peroxide. EC-CTEPH showed impaired adaptation to hypoxia, with reduced induction of glycolytic and angiogenic genes, altered morphology, delayed wound closure, and persistent oxidative stress after reoxygenation, consistent with defective hypoxia sensing. DMOG partially restored metabolic gene expression, indicating improved adaptation through HIF stabilization. Despite elevated basal ROS levels, oxidative challenge did not trigger adaptive glycolytic or angiogenic responses and induced distinct transcriptional profiles compared with controls. CTEPH endothelial cells display an altered response to hypoxia and oxidative stress, consistent with impaired hypoxia sensing and stress adaptation. This model highlights maladaptive endothelial features and provides a framework for future studies exploring HIF-targeted approaches in CTEPH.
The mechanisms underlying the development and severity of pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) remain poorly understood. To investigate the contribution of genetic factors, we performed targeted sequencing of PH-related genes in 63 patients with COPD, 51 with ILD, and 38 with idiopathic pulmonary arterial hypertension (IPAH), stratifying COPD and ILD patients according to PH severity, assessed by right heart catheterisation. Patients with ILD-associated PH harboured fewer genetic variants than those without PH, whereas an opposite trend was observed in COPD-associated PH. Variants of uncertain significance (VUS) in PAH-associated genes (BMPR2, BMPR1B) were identified in two out of 28 patients with severe COPD-PH and in one with nonsevere ILD-PH (SMAD9). VUS in extracellular matrix-related genes (THBS1, LOXL2) were also identified in four patients with severe COPD-PH, and in inflammatory-related genes (TNFAIP6) in two patients with ILD-PH. Pathogenic/likely pathogenic variants in PAH-associated genes were exclusive to IPAH. We conclude that there is limited genetic overlap between COPD-PH and ILD-PH, with a stronger genetic contribution to PH in COPD, particularly in its severe form, where a subset of patients carries VUS in PAH-associated genes or genes involved in vascular remodelling.